Eisai Dirección

Dirección controles de criterios 1/4

El CEO de Eisai's es Haruo Naito, nombrado en Jun 2003, tiene una permanencia de 20.83 años. posee directamente un 0.23% de las acciones de la empresa, con un valor de €24.76M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 2.8 años, respectivamente.

Información clave

Haruo Naito

Chief Executive Officer (CEO)

JP¥157.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	20.9yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Haruo Naito en comparación con los beneficios de Eisai?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	JP¥45b
Sep 30 2023	n/a	n/a	JP¥48b
Jun 30 2023	n/a	n/a	JP¥49b
Mar 31 2023	JP¥157m	n/a	JP¥55b
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b

Compensación vs. Mercado: La compensación total de Haruo($USD1.01M) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Haruo ha aumentado más de un 20% en el último año.

CEO

Haruo Naito (76 yo)

20.9yrs

Permanencia

JP¥157,000,000

Compensación

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Haruo Naito	CEO, Representative Corporate Officer & Director	20.9yrs	JP¥157.00m	0.23% ¥ 26.7m
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥159.00m	sin datos
Lynn D. Kramer	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	no data	JP¥211.00m	sin datos
Yanhui Feng	Senior Vice President	4.3yrs	JP¥198.00m	sin datos
Nadeem Sarwar	President	no data	sin datos	sin datos
Mitsuru Shomon	VP & CFO	1.3yrs	sin datos	sin datos
Yasushi Okada	Representative Corporate Officer	no data	sin datos	sin datos
Makoto Hoketsu	VP & Chief Information Officer	1.3yrs	sin datos	sin datos
Masatomi Akana	Chief Gov. Rel. and IR Officer	1.3yrs	sin datos	sin datos
Kenta Takahashi	Executive VP of IP	1.3yrs	sin datos	sin datos
Sayoko Sasaki	Vice President of Corporate Communications & ESG	2.3yrs	sin datos	sin datos
Teruyuki Masaka	VP & Chief HR Officer	2.3yrs	sin datos	sin datos

1.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EII no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Haruo Naito	CEO, Representative Corporate Officer & Director	9.9yrs	JP¥157.00m	0.23% ¥ 26.7m
Yuko Yasuda	Outside Independent Director	less than a year	sin datos	sin datos
Fumihiko Ike	Independent Outside Chairman	2.9yrs	sin datos	0.00035% ¥ 40.6k
Hideki Hayashi	Director	4.9yrs	sin datos	0.013% ¥ 1.5m
Toru Moriyama	Outside Independent Director	less than a year	sin datos	sin datos
Hideyo Uchiyama	Independent Outside Director	5.9yrs	sin datos	0.00027% ¥ 31.3k
Ryota Miura	Independent Outside Director	2.9yrs	sin datos	0.00021% ¥ 24.4k
Hiroyuki Kato	Director	1.9yrs	sin datos	0.0029% ¥ 342.5k
Yoshiteru Kato	Director	2.9yrs	sin datos	0.0037% ¥ 431.8k
Yumiko Miwa	Independent Outside Director	3.9yrs	sin datos	0.00032% ¥ 37.1k
Richard Thornley	Outside Independent Director	1.9yrs	sin datos	sin datos

2.9yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de EII no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Eisai Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

High number of new directors

High number of new directors

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Recent updates

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Now 20% overvalued

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings released: EPS: JP¥20.86 (vs JP¥30.14 in 3Q 2023)

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥9.73 (vs JP¥12.44 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings released: EPS: JP¥70.92 (vs JP¥93.81 in 1Q 2023)

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings released: EPS: JP¥193 (vs JP¥167 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Now 22% undervalued

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Full year 2023 earnings released: EPS: JP¥193 (vs JP¥167 in FY 2022)

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Upcoming dividend of JP¥80.00 per share at 2.2% yield

Third quarter 2023 earnings released: EPS: JP¥30.09 (vs JP¥49.43 in 3Q 2022)

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

High number of new directors

Second quarter 2023 earnings released: EPS: JP¥12.44 (vs JP¥14.04 in 2Q 2022)

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Investor sentiment improved over the past week

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Upcoming dividend of JP¥80.00 per share

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

First quarter 2023 earnings released: EPS: JP¥93.81 (vs JP¥147 in 1Q 2022)

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

High number of new directors

Full year 2022 earnings released: EPS: JP¥167 (vs JP¥147 in FY 2021)

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Full year 2022 earnings released: EPS: JP¥167 (vs JP¥147 in FY 2021)

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

High number of new directors

Eisai Co., Ltd. Announces Article About Long-Term Health Outcomes of Its Investigational Anti-Amyloid-Beta Protofibril Antibody Lecanemab in People Living

Análisis de compensación del CEO

CEO